Bluebird Bio

bluebird bio Prepares for Launch
bluebird bio Prepares for Launch
Motley Fool
Bluebird Bio
Zynteglo
beta-thalassemia
drug launches
Flag link:
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Yahoo/Zacks.com
Bluebird Bio
earnings
Flag link:
Where Will bluebird bio Be in 1 Year?
Where Will bluebird bio Be in 1 Year?
Motley Fool
Bluebird Bio
bb2121
Zynteglo
Flag link:
What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug
What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug
Forbes
Bluebird Bio
gene therapy
drug pricing
Zynteglo
beta thalassemia
Flag link:
Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks
Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks
Biopharma Dive
Bluebird Bio
gene therapy
drug manufacturing
Zynteglo
Flag link:
bluebird offers installment payments for Zynteglo gene therapy
bluebird offers installment payments for Zynteglo gene therapy
Pharmaforum
Bluebird Bio
outcome-based pricing
drug pricing
gene therapy
Zynteglo
beta thalassemia
Flag link:
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Motley Fool
Bluebird Bio
Zynteglo
drug pricing
beta thalassemia
Flag link:
Bluebird sets $1.8M price tag for blood-disease gene therapy
Bluebird sets $1.8M price tag for blood-disease gene therapy
Biopharma Dive
drug pricing
Bluebird Bio
Zynteglo
Europe
beta thalassemia
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
Patients, payers await pricing plans for bluebird's first approved gene therapy
Patients, payers await pricing plans for bluebird's first approved gene therapy
BioCentury
Bluebird Bio
gene therapy
Zynteglo
drug pricing
beta thalassemia
Flag link:
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval
Xconomy
Bluebird Bio
gene therapy
Europe
Zynteglo
EMA
beta thalassemia
Flag link:
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Motley Fool
Alexion
Ultomiris
AbbVie
Upadacitinib
risankizumab
Aimmune Therapeutics
AR-101
Bluebird Bio
LentiGlobin
Flag link:
Bluebird's not looking to break speed records with its first gene therapy launch
Bluebird's not looking to break speed records with its first gene therapy launch
Fierce Pharma
Bluebird Bio
gene therapy
beta thalassemia
Zynteglo
drug launches
Flag link:
bluebird to rollout Zynteglo starting in Germany next half
bluebird to rollout Zynteglo starting in Germany next half
BioCentury
Bluebird Bio
beta thalassemia
Germany
Zynteglo
Flag link:
bluebird bio Flies Forward
bluebird bio Flies Forward
Motley Fool
Bluebird Bio
earnings
Flag link:
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Fierce Biotech
Celgene
Bluebird Bio
bb2121
cell therapy
CAR-T
Multiple Myeloma
Flag link:
Sanofi leases its soon-to-be-former Genzyme HQ to Bluebird Bio—at a profit
Sanofi leases its soon-to-be-former Genzyme HQ to Bluebird Bio—at a profit
Fierce Pharma
Sanofi
Bluebird Bio
Kendall Square
Boston
Flag link:
Here's Why Shares of bluebird bio Slumped Today
Here's Why Shares of bluebird bio Slumped Today
Motley Fool
Bluebird Bio
Flag link:
2 Blockbuster Gene Therapy Programs to Watch in 2019
2 Blockbuster Gene Therapy Programs to Watch in 2019
Motley Fool
gene therapy
Zolgensma
Novartis
Bluebird Bio
LentiGlobin
Flag link:
First gene therapy to treat rare blood disease nears European approval
First gene therapy to treat rare blood disease nears European approval
Stat
Bluebird Bio
Europe
LentiGlobin
gene therapy
beta-thalassemia
Flag link:

Pages